Welcome to the Fall 2024 Notable New Drugs Report
New treatments target relatively small, hard-to-treat patient populations with big drug spend.
This edition of the report showcases:
- A first-in-class treatment for both A and B hemophilia which can reduce the frequency of bleeding episodes.
- A new addition to standard breast cancer therapy with improved outcomes for people with HR-positive breast cancer.
- A new drug to treat a rare congenital heart disease can reduce the risk of death by 57%.
Related healthcare insights
Guide
New treatments for NASH, schizophrenia and more are on the way.
Article
An estimated 23% of the workforce will be over age 65 by 2050 – but what does that mean for my drug plan?
Guide
Cutting-edge research in gene therapy, mRNA editing and blood enzymes pays off with powerful new advances for these drug classes.